Carnegie acted as joint global co-ordinator in the SEK 400 million rights issue in Camurus

The result of the rights issue in Camurus AB (publ) (Nasdaq Stockholm, CAMX), for which the subscription period ended on 25 March 2019, shows that 9,573,331 shares, corresponding to 99.8 percent of the offered shares, were subscribed for by exercise of subscription rights. Additionally, subscription applications corresponding to 22,169,298 shares have been received for subscription without the exercise of subscription rights, where 22,041 shares have been allotted. Consequently, the rights issue is oversubscribed and none of the guarantee undertakings have been utilized. Through the rights issue Camurus will receive approximately SEK 403 million before the deduction of transaction costs.

Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX.

Carnegie acted as joint global co-ordinator.